Company Overview of PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical developme...
100 Corporate Court
South Plainfield, NJ 07080
Founded in 1998
Key Executives for PTC Therapeutics, Inc.
Co-Founder, Chief Executive Officer and Executive Director
Total Annual Compensation: $495.0K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Chief Medical Officer
Total Annual Compensation: $329.3K
Compensation as of Fiscal Year 2014.
PTC Therapeutics, Inc. Key Developments
Parent Project Muscular Dystrophy Launches Next Phase of Genetic Testing Program, Decode Duchenne in Collaboration with BioMarin Pharmaceutical Inc., PTC Therapeutics, and Sarepta Therapeutics
Sep 30 15
Parent Project Muscular Dystrophy (PPMD) announced a collaboration with BioMarin Pharmaceutical Inc., PTC Therapeutics, and Sarepta Therapeutics, Inc. in the next phase of the highly successful Decode Duchenne program. Decode Duchenne is a nationwide program to assist individuals with Duchenne muscular dystrophy  in accessing genetic testing, interpretation, and counseling. Due to the collaboration and generous support of these partners, Decode Duchenne will provide genetic testing, interpretation, and counseling at no cost to eligible patients who are unable to access testing due to barriers such as a lack of insurance or insufficient insurance coverage. For patients with Duchenne, genetic testing is used to identify the genetic mutation and confirm the diagnosis. In addition, genetic testing can be used not only to determine a patient's eligibility for certain clinical trials, but also their compatibility for potential therapies on the horizon. Despite the benefits of testing, in some cases patients are unable to access genetic testing through their insurance provider. The program will be administered by PPMD through DuchenneConnect , a clinical registry that connects people living with Duchenne to clinical trials. To participate in Decode Duchenne, patients must: Have a confirmed diagnosis or be suspected of having Duchenne or Becker muscular dystrophy based on clinical symptoms, as assessed by their treating physician, and have a positive creatine kinase (CK) test; Have not previously had genetic testing, or must require additional genetic testing to identify a causative mutation; Provide documentation to confirm the patient's lack of insurance coverage, insufficient insurance coverage, or a denial of coverage for genetic testing; Be citizens or legal residents of the United States or Canada; The next phase of Decode Duchenne is expected to launch in October 2015.
PTC Therapeutics, Inc. Presents at Bank of America Merill Lynch Global Healthcare Conference, Sep-17-2015
Jul 30 15
PTC Therapeutics, Inc. Presents at Bank of America Merill Lynch Global Healthcare Conference, Sep-17-2015 . Venue: London, United Kingdom.
PTC Therapeutics, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-10-2015
Jul 30 15
PTC Therapeutics, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-10-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|